Product Description
EMB-01 is a novel bispecific antibody developed based on EpimAbÕs proprietary FIT-Ig¨ platform to simultaneously target EGFR and cMet on tumor cells. The resulting highly potent and durable anti-tumor effect in animal models encouraged EpimAb to rapidly advance EMB-01 to the clinic where it is currently being investigated in oncology indications. (Sourced from: https://www.epimab.com/en/news/11)
Mechanisms of Action: EGFR Inhibitor, C-Met Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Carcinoid Tumor|Colorectal Cancer|Gastrointestinal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07314294 |
EMB01X204 | P2 |
Recruiting |
Colorectal Cancer |
2027-12-30 |
12% |
2026-01-03 |
Primary Endpoints|Treatments |
NCT05176665 |
EMB01X201 | P2 |
Recruiting |
Gastrointestinal Cancer|Carcinoid Tumor |
2025-12-31 |
69% |
2024-08-27 |
Primary Endpoints|Treatments |